YDES vs ZYME

For growth investors, YD Bio Limited Ordinary Shares (YDES) is the stronger pick with 45.

8% revenue growth year-over-year, versus 38. 9% for Zymeworks Inc. (ZYME). Analysts rate Zymeworks Inc. (ZYME) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zymeworks Inc.

(ZYME) delivered a total return of -12. 2%, compared to -56. 1% for YD Bio Limited Ordinary Shares (YDES). Over 10 years, the gap is even starker: ZYME returned +104. 6% versus YDES's -56. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), YD Bio Limited Ordinary Shares (YDES) is the lower-risk stock at 0.

81β versus Zymeworks Inc. 's 0. 97β — meaning ZYME is approximately 20% more volatile than YDES relative to the S&P 500. On balance sheet safety, YD Bio Limited Ordinary Shares (YDES) carries a lower debt/equity ratio of 0% versus 7% for Zymeworks Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), YD Bio Limited Ordinary Shares (YDES) is pulling ahead at 45.

8% versus 38. 9% for Zymeworks Inc. (ZYME). Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zymeworks Inc.

(ZYME) is the more profitable company, earning -76. 6% net margin versus -276. 6% for YD Bio Limited Ordinary Shares — meaning it keeps -76. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYME leads at -87. 3% versus -286. 5% for YDES. At the gross margin level — before operating expenses — ZYME leads at 89. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, YD Bio Limited Ordinary Shares (YDES) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

81)). Both have compounded well over 10 years (YDES: -56. 1%, ZYME: +104. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.